IOBT - IO Biotech, Inc. Stock Price, Fair Value and News

1.48USD-0.05 (-3.27%)Delayed

Market Summary

USD1.48-0.05

Delayed

-3.27%

IOBT Stock Price

View Fullscreen

IOBT RSI Chart

IOBT Valuation

Market Cap

97.5M

Price/Earnings (Trailing)

-1.13

Price/Sales (Trailing)

16.58

EV/EBITDA

0.54

Price/Free Cashflow

-1.35

IOBT Price/Sales (Trailing)

IOBT Profitability

EBT Margin

-1449.26%

Return on Equity

-64.65%

Return on Assets

-57.12%

Free Cashflow Yield

-73.9%

IOBT Fundamentals

IOBT Revenue

Revenue (TTM)

5.9M

Rev. Growth (Yr)

149.71%

Rev. Growth (Qtr)

14.11%

IOBT Earnings

Earnings (TTM)

-86.1M

Earnings Growth (Yr)

-30.45%

Earnings Growth (Qtr)

-20.77%

Breaking Down IOBT Revenue

Last 7 days

4.2%

Last 30 days

-12.9%

Last 90 days

-19.1%

Trailing 12 Months

-28.8%

How does IOBT drawdown profile look like?

IOBT Financial Health

Current Ratio

9.37

IOBT Investor Care

Shares Dilution (1Y)

128.63%

Diluted EPS (TTM)

-2.03

Historical Charts for Stock Metrics

Get all data in R, Python etc through our Historical Stock Data APIs

Net sales

Year	Q1	Q2	Q3	Q4
2023	2.4M	3.5M	4.7M	5.9M
2022	0	0	0	1.4M

Get all data in R, Python etc through our Historical Stock Data APIs

Tracking the Latest Insider Buys and Sells of IO Biotech, Inc.

Filter Transactions

Datesorted ascending	Name	Buy/Sell	$ Value	Avg. Price	# Shares	Title
Feb 09, 2024	novo holdings a/s	sold	-988,411	1.5003	-658,809	-
Nov 22, 2023	burkavage brian	bought	5,175	1.035	5,000	chief accounting officer
Nov 21, 2023	burkavage brian	bought	4,950	0.99	5,000	chief accounting officer
Aug 09, 2023	elling christian e	acquired	15,012,300	1.9	7,901,230	-
Aug 09, 2023	lundbeckfond invest a/s	acquired	15,012,300	1.9	7,901,230	-
Aug 09, 2023	novo holdings a/s	bought	5,000,000	2.025	2,469,140	-
Aug 09, 2023	vivo capital ix, llc	bought	6,000,000	1.9	3,157,890	-
Aug 09, 2023	zocca mai-britt	acquired	70,370	1.9	37,037	chief executive officer
Aug 09, 2023	sullivan amy	acquired	93,825	1.9	49,382	chief financial officer
Aug 09, 2023	smith devin whittemore	acquired	9,382	1.9	4,938	general counsel

Which funds bought or sold IOBT recently?

View All Details

Datesorted ascending	Fund Name	Type	% Chg	$ Change	$ Held	% Portfolio
May 01, 2024	CONCOURSE FINANCIAL GROUP SECURITIES, INC.	sold off	-	-	-	-%
Apr 22, 2024	Vivo Capital, LLC	unchanged	-	-926,016	10,680,000	0.84%
Apr 15, 2024	WEALTH ENHANCEMENT ADVISORY SERVICES, LLC	sold off	-100	-18,800	-	-%
Feb 14, 2024	Novo Holdings A/S	unchanged	-	2,701,120	10,804,500	0.67%
Feb 14, 2024	COMERICA BANK	new	-	4.00	4.00	-%
Feb 14, 2024	BANK OF AMERICA CORP /DE/	reduced	-0.54	852,667	3,467,070	-%
Feb 14, 2024	Logos Global Management LP	unchanged	-	232,099	928,395	0.09%
Feb 14, 2024	Samsara BioCapital, LLC	unchanged	-	1,710,810	6,843,230	1.06%
Feb 14, 2024	Avoro Capital Advisors LLC	sold off	-100	-2,837,120	-	-%
Feb 14, 2024	Ancora Advisors, LLC	sold off	-100	-1,280	-	-%

Are Funds Buying or Selling IOBT?

Are funds buying IOBT calls or puts?

Calls

Puts

No. of funds holding Calls - Puts

Net Call Options

No. of funds that own IOBT

No. of Funds

Unveiling IO Biotech, Inc.'s Major ShareHolders

Date Filed	Name of Filer	Percent of Class	No. of Shares	Form Type
Feb 14, 2024	avoro capital advisors llc	0%	0	SC 13G/A
Feb 13, 2024	bank of america corp /de/	2.8%	1,844,185	SC 13G/A
Feb 13, 2024	stonepine capital management, llc	5.4%	3,641,345	SC 13G/A
Feb 13, 2024	novo holdings a/s	11.1%	7,557,393	SC 13D/A
Feb 13, 2024	hbm healthcare investments (cayman) ltd.	6.0%	3,944,492	SC 13G/A
Dec 18, 2023	samsara biocapital, l.p.	5.5%	3,640,015	SC 13G
Sep 07, 2023	kurma partners	17.18%	12,253,230	SC 13G
Aug 16, 2023	stonepine capital management, llc	5.8%	3,950,616	SC 13G
Aug 15, 2023	hbm healthcare investments (cayman) ltd.	8.19%	5,523,439	SC 13G/A
Aug 14, 2023	lundbeckfond invest a/s	29.6%	21,851,920	SC 13D/A

Recent SEC filings of IO Biotech, Inc.

View All Filings

Date Filed	Form Type	Document
Apr 26, 2024	8-K	Current Report
Apr 24, 2024	ARS	ARS
Apr 24, 2024	DEF 14A	DEF 14A
Apr 24, 2024	DEFA14A	DEFA14A
Mar 22, 2024	10-K/A	Annual Report
Mar 18, 2024	4	Insider Trading
Mar 18, 2024	4	Insider Trading
Mar 18, 2024	4	Insider Trading
Mar 18, 2024	4	Insider Trading
Mar 18, 2024	4	Insider Trading

Peers (Alternatives to IO Biotech, Inc.)

Name	Mkt Capsorted ascending	Revenue	Price %, 1M	Returns, 1Y	P/E	P/S	Rev 1-Yr	Inc 1-Yr
LARGE-CAP
MRNA	47.9B	6.8B	23.52%	-6.94%	-8.03	7	-64.45%	-224.75%
HILS	22.4B	152.6K	-0.77%	465779.94%	-2.4K	146.8K	-	-9.98%
ALNY	19.3B	2.0B	0.99%	-25.83%	-58.02	9.62	75.20%	68.82%
BMRN	15.7B	2.5B	-4.94%	-13.58%	76.24	6.34	13.74%	186.89%
INCY	12.1B	3.8B	-2.80%	-18.78%	16.19	3.2	8.58%	129.81%
MID-CAP
APLS	5.7B	396.6M	-16.72%	-43.78%	-10.82	14.42	425.83%	18.94%
BBIO	5.2B	107.9M	-4.79%	106.15%	-9.53	48.09	54.84%	-28.31%
AXSM	3.5B	270.6M	1.74%	5.10%	-14.81	13.09	440.80%	-27.84%
ARWR	3.0B	240.7M	-7.74%	-39.00%	-10.2	12.18	-1.03%	-92.09%
ACAD	2.8B	726.4M	-7.55%	-20.97%	-45.79	3.86	40.45%	71.62%
SMALL-CAP
CPRX	1.7B	398.2M	-4.91%	-11.58%	24.31	4.36	85.90%	-14.05%
NVAX	687.2M	983.7M	8.15%	-35.14%	-1.26	0.7	-50.36%	17.16%
CRBP	408.0M	881.7K	0.99%	345.87%	-9.15	466.16	-77.61%	-5.33%
INO	282.8M	4.9M	-1.94%	21.49%	-2.09	58.11	-54.97%	51.71%
IBIO	6.9M	2.1M	-32.65%	86.79%	-0.25	2.14	-13.45%	66.37%

IO Biotech, Inc. News

Latest updates

IO Biotech, Inc. Earnings Report: Key Takeaways & Analysis

Income Statement (Last 12 Months)

Income Statement (Quarterly)
Description	(%) Q/Q	2023Q4	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1
Revenue	14.1%	1,949,000	1,708,000	1,196,000	1,028,000	780,500	457,000	158,000	15,000
Operating Expenses	20.0%	28,183,000	23,484,000	21,852,000	17,924,000	20,388,500	15,865,000	18,161,000	17,010,000
S&GA Expenses	10.0%	6,413,000	5,829,000	5,348,000	6,024,000	5,956,000	5,843,000	5,935,000	6,704,000
R&D Expenses	23.3%	21,770,000	17,655,000	16,504,000	11,900,000	14,432,500	10,022,000	12,226,000	10,306,000
EBITDA Margin	12.9%	-14.46	-16.61	-20.64	-28.59	-49.47	-	-	-
Interest Expenses	-	-	-	-	-	-2,000	78,000	102,000	123,000
Income Taxes	188.0%	352,000	-400,000	500,000	400,000	965,500	115,000	100,000	100,000
Earnings Before Taxes	-16.8%	-25,829,000	-22,118,000	-20,646,000	-16,638,000	-19,083,500	-15,573,000	-18,391,000	-17,138,000
EBT Margin	13.0%	-14.49	-16.65	-20.78	-28.75	-49.76	-	-	-
Net Income	-20.8%	-26,182,000	-21,679,000	-21,178,000	-17,044,000	-20,071,000	-15,688,000	-18,495,000	-17,204,000
Net Income Margin	13.8%	-14.64	-16.98	-21.38	-29.44	-50.69	-	-	-
Free Cashflow	-43.0%	-22,907,000	-16,014,000	-18,301,000	-14,838,000	-12,875,000	-13,466,000	-13,118,000	-20,960,000

Balance Sheet

(In Millions)

(*) denotes actual numbers (not divided by Millions)
Balance Sheet											(In Millions)
Description	(%) Q/Q	2023Q4	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2020Q4
Assets	-12.7%	151	173	118	137	152	162	183	202	222	52.00	-
Current Assets	-12.5%	147	168	113	132	148	158	179	199	222	52.00	6.00
Cash Equivalents	-13.5%	143	166	110	129	143	151	170	188	212	45.00	3.00
Net PPE	6.3%	1.00	1.00	1.00	1.00	1.00	1.00	0.00	0.00	0.00	-	-
Liabilities	17.3%	18.00	15.00	13.00	13.00	13.00	9.00	10.00	8.00	10.00	34.00	3.00
Current Liabilities	21.0%	16.00	13.00	11.00	10.00	11.00	6.00	9.00	6.00	10.00	34.00	3.00
Shareholder's Equity	-15.5%	133	158	105	124	139	153	172	194	212	-	-
Retained Earnings	-11.0%	-263	-237	-216	-194	-177	-157	-141	-123	-106	-84.97	-38.40
Additional Paid-In Capital	0.4%	407	405	330	329	327	325	323	321	320	2.00	1.00
Shares Outstanding	0%	66.00	66.00	29.00	29.00	29.00	29.00	29.00	29.00	29.00	-	-
Float	-	-	-	31.00	-	-	-	73.00	-	-	-	-

Cashflow (Last 12 Months)

(In Thousands)

(*) denotes actual numbers (not divided by Thousands)
Cashflow (Quarterly)														(In Thousands)
Description	(%) Q/Q	2023Q4	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2021Q1	2020Q4	2020Q3
Cashflow From Operations	-42.6%	-22,795	-15,990	-18,262	-14,690	-12,526	-13,348	-13,011	-20,844	-19,240	-8,171	-9,343	-3,892	-	-
Share Based Compensation	-47.9%	1,558	2,989	1,624	1,888	1,661	2,401	1,358	1,620	1,299	483	5.00	4.00	-	-
Cashflow From Investing	-366.7%	-112	-24.00	-39.00	-148	-349	-118	-107	-116	-	-	-	-	-	-
Cashflow From Financing	-Infinity%	-10.00	-	-	-	-	-	-	-	187,543	-	-	65,408	-	-

Get Full Access to Grufity – and Unlimited Downloads

Gain full access to fair value, watchlists, stock screener, unlimited page visits, and additional features by joining as a member today for just $1.99.

Try For Just $1.99

IOBT Income Statement

2023-12-31

Consolidated Statements of Operations and Comprehensive Loss - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2023	Dec. 31, 2022
Operating expenses
Research and development	$ 67,829	$ 46,986
General and administrative	23,614	24,438
Total operating expenses	91,443	71,424
Loss from operations	(91,443)	(71,424)
Other income (expense)
Currency exchange gain, net	331	130
Interest income	5,881	1,411
Interest expense		(302)
Total other income, net	6,212	1,239
Loss before income tax expense	(85,231)	(70,185)
Income tax expense	852	1,273
Net loss	(86,083)	(71,458)
Net loss attributable to common shareholders	$ (86,083)	$ (71,458)
Net loss per common share, basic	$ (1.98)	$ (2.48)
Net loss per common share, diluted	$ (1.98)	$ (2.48)
Weighted-average number of shares used in computing net loss per common share, basic	43,539,976	28,815,267
Weighted-average number of shares used in computing net loss per common share, diluted	43,539,976	28,815,267
Other comprehensive loss
Net loss	$ (86,083)	$ (71,458)
Foreign currency translation	472	(8,652)
Total comprehensive loss	$ (85,611)	$ (80,110)

IOBT Balance Sheet

2023-12-31

Consolidated Balance Sheets - USD ($) $ in Thousands	Dec. 31, 2023	Dec. 31, 2022
Current assets
Cash and cash equivalents	$ 143,193	$ 142,590
Prepaid expenses and other current assets	4,062	5,629
Total current assets	147,255	148,219
Restricted cash	268	268
Property and equipment, net	847	741
Right of use lease asset	2,259	2,493
Other non-current assets	89	84
Total non-current assets	3,463	3,586
Total assets	150,718	151,805
Current liabilities
Accounts payable	3,878	4,004
Lease liability - current	655	515
Accrued expenses and other current liabilities	11,184	6,157
Total current liabilities	15,717	10,676
Lease liability - noncurrent	1,839	2,275
Total non-current liabilities	1,839	2,275
Total liabilities	17,556	12,951
Commitments and contingencies (Note 9)
Stockholders' equity
Preferred stock, par value of $0.001 per share; 5,000,000 shares authorized, no shares issued and outstanding as of December 31, 2023 and 2022
Common stock, par value of $0.001 per share; 300,000,000 shares authorized at December 31, 2023 and December 31, 2022; 65,880,914 and 28,815,267 shares issued and outstanding as of December 31, 2023 and December 31, 2022, respectively	66	29
Additional paid-in capital	406,587	326,705
Accumulated deficit	(263,822)	(177,739)
Accumulated other comprehensive loss	(9,669)	(10,141)
Total stockholders' equity	133,162	138,854
Total liabilities and stockholders' equity	$ 150,718	$ 151,805

About IO Biotech, Inc.

IO Biotech, Inc., a clinical-stage biopharmaceutical company, develops immune-modulating cancer therapies based on the T-win technology platform. The company's lead product candidate, IO102-IO103, which is designed to target immunosuppressive proteins, such as Indoleamine 2,3-dehydrogenase (IDO), and programmed death-ligand (PD-L1) that is in phase 3 clinical trial to treat melanoma, as well as in phase 1 clinical trial to treat lung, head and neck, bladder, and melanoma cancer. It also develops IO112, a product candidate that contains a single Arginase 1-derived peptide designed to target T cells that recognize epitopes derived from Arginase 1 for the treatment of cancers. The company was incorporated in 2014 and is based in Copenhagen, Denmark.

CEO	Dr. Mai-Britt Zocca Ph.D.
WEBSITE	iobiotech.com
INDUSTRY	Biotechnology
EMPLOYEES	57

IO Biotech, Inc. Frequently Asked Questions

What is the ticker symbol for IO Biotech, Inc.? What does IOBT stand for in stocks?

IOBT is the stock ticker symbol of IO Biotech, Inc.. Every public company that trades on a stock exchange gets a ticker symbol.

What is the market capital of IO Biotech, Inc. (IOBT)?

As of Fri May 03 2024, market cap of IO Biotech, Inc. is 97.5 Million. The market capitalization is calculated by multiplying the stock price with the number of shares outstanding.

What is the fair value of IOBT stock?

You can check IOBT's fair value in chart for subscribers.

What is the fair value of IOBT stock?

You can check IOBT's fair value in chart for subscribers. The fair value of IO Biotech, Inc. is provided for various growth and macro-economic scenarios from very pessimiatic to very optimistic assumptions. These fair values are estimates from Grufity's Fair Value model based on company's past performance. However, past performance of IO Biotech, Inc. is no guarantee of future performance. These fairvalue estimates should only be used as one of the inputs in your stock analysis. We provide model's historical fair value estimates for IOBT so that you know how good or bad the model has been in the past so you can discard it if needed. There are others that provide fair values of stocks such as wallmine, finbox, gurufocus and finviz. Most provide point in time estimates. We provide a history of our models fair value estimates so that you can get a sense of it's usefulness. Otherwise this data point is of little use.

Is IO Biotech, Inc. a good stock to buy?

The fair value guage provides a quick view whether IOBT is over valued or under valued. Whether IO Biotech, Inc. is cheap or expensive depends on the assumptions which impact IO Biotech, Inc.'s fair value. We provide several scenarios of inflation and growth to encompass these range of assumptions for IOBT.

What is IO Biotech, Inc.'s Price to Earnings (PE) and Price to sales (PS) ratio?

As of Fri May 03 2024, IOBT's PE ratio (Price to Earnings) is -1.13 and Price to Sales (PS) ratio is 16.58. The price to earnings and price to sales ratio are two most important valuation metrics for any company. PE ratio tell us the number of years of earnings investors are ready to pay for owning the company. Historically, S&P500 price to earnings ratio has fallen below 12 during periods of gloom and gone past 30 during periods of euphoria. IOBT PE ratio will change depending on the future growth rate expectations of investors.